

Outcomes of chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in non-resectable locally recurrent rectal cancer

Luca Sorrentino^{a*#}, MD, Andrea Scardino^{a#}, MD, Luigi Battaglia^a, MD, Raffaella Vigorito^b, MD, Giovanna Sabella^c, MD, Filippo Patti^d, MD, Michele Prisciandaro^e, MD, PhD, Elena Daveri^f, PhD, Alessandro Gronchi^g, MD, Filiberto Belli^{*a}, MD, Marcello Guaglio^a, MD

^aColorectal Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^bDepartment of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^c1st Pathology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^dRadiation Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^eDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^fTranslational Immunology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^gSarcoma Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Supplementary Tables

Supplementary Table S1. Univariate and multivariate analyses for overall survival

	Univariate analysis			Multivariate analysis		
	HR	95%CI	P value	HR	95%CI	P value
Time to local recurrence	1.00	0.98-1.01	0.446	-	-	-
CEA	1.00	0.99-1.01	0.291	-	-	-
CA19.9	1.01	1.00-1.01	0.14	1.01	0.99-1.01	0.245
Size on MRI	1.00	0.98-1.02	0.964	-	-	-
Synchronous distant metastases	1.21	0.45-2.77	0.676	1.49	0.43-4.48	0.495
Pelvic localization of LRRC						
S1a-b-c	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)
S2a-b	0.52	0.19-1.29	0.168	0.64	0.19-2.03	0.447
S3	0.55	0.245-1.25	0.149	0.68	0.23-1.88	0.465
Therapeutic approach						
Chemotherapy ± radiotherapy	0.13	0.05-0.37	<0.001	0.19	0.06-0.61	0.003
Debulking ± chemotherapy ± radiotherapy	0.15	0.05-0.45	<0.001	0.15	0.04-0.55	0.004
No treatment	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)
KRAS status (mutated vs. wild-type)	1.90	0.75-4.77	0.167	-	-	-
Previous systemic chemotherapy	2.36	1.01-6.16	0.059	-	-	-